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Abstract
β-Secretase1 (BACE1) protein concentrations and rates of enzyme activity, analyzed in human bodily fluids, are
promising candidate biological markers for guidance in clinical trials investigating BACE1 inhibitors to halt or delay
the dysregulation of the amyloid-β pathway in Alzheimer’s disease (AD). A robust body of evidence demonstrates
an association between cerebrospinal fluid/blood BACE1 biomarkers and core pathophysiological mechanisms of
AD, such as brain protein misfolding and aggregration, neurodegeneration, and synaptic dysfunction.
In pharmacological trials, BACE1 candidate biomarkers may be applied to a wide set of contexts of use (CoU),
including proof of mechanism, dose-finding, response and toxicity dose estimation. For clinical CoU, BACE1
biomarkers show good performance for prognosis and disease prediction.
The roadmap toward validation and qualification of BACE1 biomarkers requires standardized pre-analytical and
analytical protocols to reduce inter-site variance that may have contributed to inconsistent results.
BACE1 biomarker-drug co-development programs, including biomarker-guided outcomes and endpoints, may
support the identification of sub-populations with a higher probability to benefit from BACE1 inhibitors with a
reduced risk of adverse effects, in line with the evolving precision medicine paradigm.
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Introduction
β-Site amyloid precursor protein (APP) cleaving enzyme
1 (BACE1) is a type I transmembrane aspartyl protease
widely expressed in the brain, particularly in neurons,
oligodendrocytes, and astrocytes [1–3]. BACE1 is
expressed at the plasma endothelial membrane and in
the endosomal compartments and has been detected in
healthy synaptic terminals. BACE1 functions as the β-
secretase enzyme by cleaving the transmembrane APP
to release the β-stubs and represents the rate-limiting
catalytic step for Aβ production (see Fig. 1) [1–3].
High BACE1 concentrations (probably reflecting gene
expression levels) and enzymatic activity were found in
human AD brain extracts, consistent with experimental
evidence that neurons express higher levels of Aβ in AD
compared to “cognitively healthy aging.” In addition, a
relatively large accumulation of BACE1 was found in
neuritic dystrophies in close proximity of Aβ plaques
both in AD amyloidogenic transgenic mouse models and
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: avergallo@outlook.com
1Sorbonne University, GRC no 21, Alzheimer Precision Medicine (APM),
AP-HP, Pitié-Salpêtrière Hospital, Paris, France
Full list of author information is available at the end of the article
Hampel et al. Alzheimer's Research & Therapy          (2020) 12:130 
https://doi.org/10.1186/s13195-020-00686-3
in AD brains, and this presence may promote cyclic Aβ
production [3, 5, 6].
Although BACE1 mutations have not yet been linked
to AD risk, genetic variants surrounding the β-secretase
site in the APP (including the Swedish mutation KM/
NL, the Italian variant A673V, and the A673T) are asso-
ciated with either higher or lower affinity for BACE1 to
initiate APP cleavage, thus exerting a protective or risk
effect, respectively [3].
The reported translational results provide robust proof
of principle for the pathophysiological and pharmaco-
logical model, indicating that reducing the β-cleavage of
APP may be a resilience mechanism for AD [3].
With the advent of oral and blood-brain barrier
(BBB)-permeable inhibitors, BACE1 has become a cen-
tral target in several drug AD R&D pipelines. Despite in-
tense pharmacological efforts, all clinical trials so far
have been discontinued for futility or signs of cognitive
worsening or some systemic toxic effects, thus raising
relevant safety and efficacy concerns [7, 8].
One of the most significant issues after a first reflec-
tion on discontinued clinical trials is that they did not
introduce any direct BACE1 biomarkers for any relevant
context of use (CoU), such as proof of mechanism, dose-
finding, and efficacy/safety measures. Implementation of
existing BACE1 biomarkers would support the mapping
of drug response, optimization of go/no-go decision-
making, and mitigation of side effects due to non-
specific or too high BACE1 inhibition [3].
Search strategy and selection criteria
The narrative inherent to this review article is based on
the authors’ knowledge and experience in the field. As
such, no systematic literature search was performed.
BACE1 biomarkers in the cerebrospinal fluid (CSF)
BACE1 protein concentrations, probably reflecting levels
of gene expression, and rates of enzymatic activity,
have been measured in human CSF samples to investi-
gate their diagnostic/predictive values as well as their
association with critical pathophysiological alterations of
AD, including the amyloid-β pathway, tau pathophysi-
ology, neurodegeneration, and synaptic dysfunction [3].
CSF BACE1 biomarker: diagnostic and predictive
performance
The first study analyzed BACE1 CSF concentrations and
activity in a pooled cohort of cogntively healthy control
Fig. 1 Schematic representation of amyloidogenic and non-amyloidogenic pathways. Footnote: Three main proteases—α-, β-, and γ-secretases—are
involved in APP processing through the amyloidogenic pathway (sequential cleavage by β- and γ-secretases), promoting amyloid-β (Aβ) production,
and the non-amyloidogenic pathway in which Aβ is cleaved in the middle, either directly by α-secretase (generating soluble APPα) or by the
sequential cleavage by β-secretase and α-secretase (generating shorter Aβ species such as Aβ1–15 and Aβ1–16). The two pathways lead to the
production of different by-products with different intrinsic functional properties, putative physiological roles, and pathophysiological potential. In
particular, BACE1 serves as the β-secretase enzyme by cleaving the transmembrane APP to release the β-stubs. BACE1 cleavage of APP represents the
rate-limiting step for Aβ production. Cleavage of APP by BACE1 liberates the soluble N-terminus of APP, while the C-terminal fragment (CTF-β or C99)
remains bound to the membrane. To produce Aβ, the fragment CTF-β is cleaved by γ-secretase, an aspartyl-type protease membrane protein
complex, which finally releases Aβ into the extracellular space and the APP intracellular domain into the cytoplasm. The γ-secretase consists of
different components. The catalytic components of the membrane-embedded tetrameric γ-secretase complex are represented by presenilins 1 and 2,
intramembrane-cleaving proteases (I-CLIPs), responsible for generating the Aβ carboxyl terminus from APP. In a parallel competing non-amyloidogenic
pathway, APP is cleaved either by α-secretase or η-secretase to release two additional variants of the APP ectodomain, namely sAPP-α and sAPP-η. In
vitro studies have shown that ADAM-10, a disintegrin and metalloprotease belonging to the family proteases, is the major α-secretase responsible for
the ectodomain shedding of APP in the mouse brain and likely to be active in humans. APP is a type I transmembrane protein, highly expressed in
neurons and abundant at the synapse. Although a full understanding of its function remains elusive, studies have suggested a role in the remodeling
of dendritic spines, neurotransmission, synaptic plasticity, and maintenance of excitation-inhibition (E/I) balance. Soluble sAPPα and sAPPβ are
hypothesized to modulate basal synaptic transmission and short-term synaptic facilitation likely through GABAB receptor subunit 1a-mediated synaptic
effect. Note: Adapted from [4]. Reproduced with permission
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(HC) individuals, clinically diagnosed patients with AD
dementia (ADD), and individuals with mild cognitive
impairment (MCI) [9].
The authors reported that individuals in which
BACE1 both enzymatic activity and protein levels are
in the higher ranges showed an increased relative risk
of association with the MCI group when compared to
HC or ADD individuals. The finding of elevated
BACE1 biomarkers in individuals with MCI compared
to ADD was discussed in relation to extensive den-
dritic remodeling and neuronal loss characterizing
dementia stages [9].
Zetterberg and colleagues investigated BACE1 activity
in a comparable pooled cohort, reporting a statistically
significant difference between patients with ADD and
HC individuals, but not between ADD patients and a
diagnostic group of HC combined with MCI individuals
[10]. When further differentiating the group of MCI in-
dividuals into ADD converters and non-converters, they
found higher mean BACE1 activity in the former sub-
group than in the latter one [10]. Such results were cor-
roborated in subsequent studies [11–13].
In a separate study, Perneczky and colleagues assessed
BACE1 activity in a population of 342 individuals, in-
cluding HC, stable MCI, converted MCI individuals, and
ADD patients. Contrary to these findings, no significant
differences in BACE1 activity were found between the
investigated groups. The authors argued that such unex-
pected results could be partly due to the different used
assays, which may have impacted BACE1 activity due to
higher intra-assay variability [14].
Likewise, Savage and colleagues found no significant
difference regarding BACE1 activity between individuals
with HC, MCI, and ADD. In line with the argumentation
of Perneckzy and colleagues, they hypothesized that the
wide inter-subject variability of BACE1 activity along
with technical differences of laboratory assays could
have limited the analytical standardization and clinical
validation of the CSF BACE1 diagnostic candidate
biomarker [15].
CSF BACE1 and amyloid-β biomarkers
Studies investigating CSF BACE1 biomarkers and indica-
tors of brain accumulation of Aβ, including CSF 42-
amino acid forms of amyloid-β protein (Aβ42) and Aβ
positron emission tomography (Aβ-AΒ-PET), do not
show consistent results, as some studies did not find any
significant association [10, 14, 16, 17], while other
studies showed significant correlations [18–20].
A significant association was found in studies that
stratified the whole study population according to the
clinical diagnosis, reporting positive correlations only in
HC individuals and patients with ADDs [18–20], but not
in individuals with MCI [18]. There is no clear biological
explanation for the variation of results across different
studies but rather a potential methodological issues re-
lated to employing different study designs, populations,
and assays. The diverging results (i.e., Aβ42 is a product
of the BACE1 pathway and thus an association was
expected) have generated some discussion.
Some authors raised the question of whether Aβ42
monomers truly provide comprehensive information on
the whole Aβ pathway that encompasses small aggregation
species, oligomers, protofibrils, fibrils, and eventually se-
nile plaques [3, 10]. Effective clearance of Aβ aggregates
will impact the concentrations of Aβ42 in CSF as well.
Therefore, the whole unfolding of the amyloid-β pathway
can account for a non-linear association between BACE1
and Aβ42 monomers (see below). Despite the lack of a ro-
bust correlation of CSF Aβ42 with BACE1 concentrations,
a multimodal study showed that CSF BACE1 activity is
correlated with a global uptake of the Pittsburgh Com-
pound B PET (PiB-PET) tracer, a radiotracer that binds to
the fibrillary component of amyloid plaques [21].
BACE1 CSF parameters correlate, at least in part, with
other Aβ markers. In particular, a strong positive correl-
ation between BACE1 and levels of Aβ40, sAPP-α, and
sAPP-β has been reported. Interestingly, although sAPP-
α is a by-product of the alternative pathways of α-
secretase, it negatively correlates with BACE1 [10]. This
finding may be explained through collinearity between
sAPP-α and sAPP-β that are highly associated with one
another or by the fact that both by-product may reflect
the rate of APP processing [10].
CSF BACE1 and biomarkers of tau-related
pathophysiology
Concerning the association between BACE1 and tau-
related pathophysiology, multiple groups—using differ-
ent methodological approaches and study designs—
found a positive correlation between CSF BACE1 bio-
markers and CSF tau phosphorylated at threonin181 (t-
tau and p-tau, respectively) [22].
Experimental evidence and translational studies can
help explain the association between p-tau and the
amyloid-β pathway, including the putative upstream role
of BACE1. Indeed, injection of Aβ fibrils into the brains
of P301L mutant tau transgenic mice triggers a fivefold
increase in NFTs in cell bodies within the amygdala
where neurons project to the injection sites [23]. In an-
other study, crossing transgenic mice showing the spread
of tau from the entorhinal cortex to other brain regions
with APP/PS1 mice showed that cortical amyloid depos-
ition caused a dramatic increase in tau spreading to dis-
tal brain regions. Hence, several findings point toward
an upstream role of Aβ, and on an inferring speculative
basis BACE1, on tau phosphorylation and neurofibrillary
tangle generation by facilitating and promoting the
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conversion of tau from a normal to a toxic state, which
may enhance Aβ toxicity via a feedback loop [24, 25].
Such experimental evidence supports the data-driven
(biomarker-based) hypothetical model of AD clinical-
biological continuum whereby brain accumulation of Aβ
may either facilitate being permissive to spreading of tau
pathology that is tightly associated with the clinical evo-
lution of the disease [22].
CSF BACE1 biomarkers and neurodegeneration
CSF BACE1 biomarkers have been investigated in rela-
tion to hippocampal volume loss, a biomarker of re-
gional neurodegeneration occurring during early stages
of AD.
The only published structural MRI study reported that
an increase in CSF BACE1 activity is associated with bi-
lateral decreased hippocampus volume [11]. The inter-
pretation of this finding is unclear; however, it may
suggest a BACE1-mediated neurotoxicity. The observed
BACE1 activity in CSF inversely correlating with hippo-
campal volume supports the hypothesis that elevated
BACE1 may induce downstream amyloidogenic effects
by triggering stepwise neurodegeneration leading to
hippocampal atrophy.
Evidence indicating an association between BACE1 and
neurodegeneration can be derived from studies reporting
positive correlations between CSF BACE1 biomarkers and
CSF total tau protein [9–12, 14–20, 26], a surrogate
marker of axonal damage and neuronal loss. It is conceiv-
able that BACE1 is released into CSF by degenerating
neurons and that the concentrations may correlate with
the severity of neurodegeneration and the progression of
synaptopathy and neuronal loss. Dysregulation of synaptic
BACE1 functions may account in part for a non-
amyloidogenic impact on synaptic homeostasis.
Beyond any preliminary data-driven and knowledge-
based consideration, it must be outlined that major parts
of evidence regarding the association between BACE1
and tau biomarkers in CSF have been studied cross-
sectional. Longitudinal observational studies are needed
to investigate the spatial-temporal relationship between
BACE1 biomarker expression, gene expression levels
and activity, and neurodegeneration.
By contrast, the results of the phase 3 trial of verubece-
stat (12 or 40mg/day) conducted in mild-to-moderate AD
patients (EPOCH, ClinicalTrials.gov NCT01739348)
showed significant BACE1 inhibition correlating with de-
creased hippocampal volumes [3]. Although a univocal in-
terpretation of this trial result is challenging, it has been
hypothesized that there is an over inhibition of BACE1
regulation of synaptic substrates and or physiological
functions of Aβ species, essential also for hippocampal
homeostasis [3] (see Fig. 1 for more details about the amy-
loidogenic pathway). Follow-up analysis is needed in
BACE1 inhibitor trials to ascertain whether this hippo-
campal effect is related to the cognitive worsening re-
ported in some studies and whether it may reversible.
CSF BACE1 and synaptic biomarkers
Two studies investigated the association between CSF
BACE1 and biomarkers of synaptic dysfunction. De Vos
and colleagues analyzed CSF BACE1 and neurogranin
(NGR)—a dendritic protein proposed as a biomarker of
hippocampal synaptic impairment [27]—in a pooled cohort
of HC individuals HC and positive Aβ biomarkers individ-
uals diagnosed with MCI or ADD [18]. Despite no signifi-
cant inter-group differences, they found that the NGR/
BACE1 ratio differentiates both the MCI and ADD diagnos-
tic groups from the HC individuals group with good accur-
acy [18]. The NGR/BACE1 ratio also showed potential
prognostic value since individuals with higher concentra-
tions had a more severe cognitive decline at follow-up [18].
In agreement with De Vos and colleagues, a recent re-
port showed that NGR/BACE1 ratio levels are (i) ele-
vated in both individuals with subjective cognitive
decline (SCD) and MCI compared to HC individuals,
(ii) associated with smaller hippocampal and amygdala
volumes, and (iii) correlate with worse baseline and
longitudinal cognitive performance [28].
A recent study investigated a broad set of candidate bio-
markers tracking distinct pathophysiological processes in
patients with AD and reported a positive cross-sectional
correlation between BACE1 CSF concentrations and NGR
[20]. Interestingly, another group reported that the CSF
NGR/BACE1 ratio, along with core AD biomarkers, dis-
plays good accuracy to distinguish between depression
with cognitive impairment and AD dementia [29].
Given the established neurobiological overlap among de-
pression, MCI, and AD, the NGR/BACE1 ratio may repre-
sent a suitable clinical tool for the AD diagnostic workup
[30]. Further prospective longitudinal studies are needed to
understand the role of the NGR/BACE1 ratio as a bio-
marker to improve the classification between non-neurode-
generative forms of MCI, including but not exclusively
depression, and early AD.
The understanding of the relationship between BACE1
and synaptic homeostasis remains an unmet objective.
There is evolving experimental evidence, i.e., data from
conditional deletion of BACE1 in mouse models, that
points at BACE1 as a molecular orchestrator of hippo-
campal synaptic remodeling at the dendritic and axonal
level [3, 7]. Arguably, BACE1 overactivation may exces-
sively accelerate synaptic turnover until it triggers down-
stream detrimental pathways resulting in synaptic
damage. The generated hypothesis is further supported
by studies investigating the association between BACE1
and other candidate biomarkers of neurodegeneration
and synaptic loss.
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CSF BACE1 biomarkers and the APOE ε4 allele
Ewers and colleagues reported an association of the apoli-
poprotein E (APOE) ε4 allele with increased BACE1 activ-
ity in both patients with ADD and subjects with MCI
compared to HC individuals [31]. This finding is in agree-
ment with experimental models of AD, indicating in-
creased activity of BACE1 in individuals carrying the
APOE ε4 allele [32]. It is unclear whether this correlation
is induced by APOE ε4 allele in promoting Aβ deposition,
which subsequently can induce increase of BACE1 activ-
ity. Consistently, in-human neuropathological studies
show higher concentrations of BACE1 in HC individ-
uals or ADD patients, carrying the APOE ε4 allele [33].
Two independent studies did not show any association be-
tween the APOE genotype and BACE1 concentrations or
rates of activity. Of note, the two studies differed signifi-
cantly with each other and compared to other investiga-
tions, in terms of experimental design, including the assay
utilized [15, 16]; see the section “Potential explanation of
controversial results in CSF (and blood-based) BACE1
studies” for a more in-depth argumentation.
CSF-based studies provide evidence that BACE1 bio-
markers, both protein concentrations and enzymimatic
activity, support further analytical and clinical investiga-
tions in patients with AD to investigate their potential as
candidate biomarkers suitable for clinical practice (i.e.,
early diagnosis, prediction, and progression) and
pharmacological trials targeting BACE1 (i.e., target
engagement and efficacy response, among others).
Further studies with longer follow-up, standardized pre-
analytical procedures, and analytical protocols are
required to address the open questions based on conflict-
ing study data.
BACE1 blood-based biomarkers
BACE1 biomarkers in plasma
While BACE1 is primarily expressed in the CNS, the
protease is expressed in platelets, leukocytes, and is cir-
culating as a soluble protein in the plasma.
For different CoU, blood-based biomarkers provide
unique opportunities and decision-making tools in clinical
trial programs. Blood-based biomarkers have numerous
advantages, i.e., they are widely accessible and minimally
invasive and are more time- and cost-effective for health-
care systems compared with CSF. In particular, they are
appropriate tools to inform biomarker-guided medicine
applied to individuals with preclinical AD [27].
Both BACE1 activity and protein concentrations in
blood (mostly plasma but in some cases serum) are sig-
nificantly increased in MCI individuals or patients with
ADD compared to HC individuals, with a trend across
different disease stages reflecting the direction of expres-
sion of the reported CSF biomarkers [34–36].
Shen and colleagues reported a study in which both
blood BACE activity and protein concentration were mea-
sured and explored in parallel with correlations of CSF
AD core biomarkers [36]. The population included indi-
viduals with ADD, HC, MCI converters to AD, and MCI
stable at follow-up. They showed that BACE1 activity was
elevated in both individuals with ADD and MCI con-
verters when compared to stable MCI or HC individuals;
at the same time, BACE1 protein concentrations were sig-
nificantly increased in individuals with ADD compared to
HC or stable MCI, while BACE1 concentrations in con-
verter MCI individuals were significantly elevated com-
pared to subjects with stable MCI, but not compared to
the HC group [36]. BACE1 activity was positively corre-
lated with CSF t-tau protein and negatively correlated with
CSF Aβ42, further supporting a link between the plas-
matic biomarker and brain AD pathology [36].
A recent plasma-based study tested associations be-
tween plasma BACE1 concentrations and the degree of
cerebral accumulation of Aβ in a cohort of HC with sub-
jective memory complaints (SMC), a condition associated
with increased risk for AD. For this objective, brain accu-
mulation of Aβ was investigated using Aβ positron emis-
sion tomography (PET) imaging (Aβ-PET) [37] showing,
for the first time, that plasma BACE1 concentrations im-
pact the level of brain Aβ in individuals with SMC [37].
The same study further investigated the question of
whether other relevant biological factors, such as sex, be-
sides the APOE ε4 allele and age, may affect plasma BACE1
concentrations [37]. They found highly significantly in-
creased baseline and longitudinal mean concentrations of
BACE1 in women compared to men, irrespective of age
and time [37]. These results indicate a potential sexual di-
morphism in plasma BACE1 concentrations, in agreement
with experimental evidence about the role of estradiol in
the control of BACE1 expression [38].
BACE1 assessed in platelets
Studies conducted in platelets show an increase of
BACE1 protein concentrations and higher activity rates
in individuals with ADD and or MCI compared to HC
[39–41]. One study did not find differences between in-
dividuals with HC and MCI, while Decourt and col-
leagues found decreased BACE1 protein concentrations
in individuals with ADD when compared to HC [42].
Another platelet-based study reported that patients
with ADD treated with a stable 6-month dose of done-
pezil, but not cognitively healthy controls, showed
downregulation of BACE1 gene expression in platelets
[43]. Given the consistency between the study results
and AD pathophysiology, including BACE1 overexpres-
sion, the authors argued that BACE1 platelet levels
should be investigated to ascertain whether they might
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represent an additional exploratory outcome measure to
employ in BACE1 inhibitor trials.
BACE1 transcriptomic studies in blood
Besides assessing enzymatic biomarkers, molecular biol-
ogy investigations of BACE1 have used blood samples.
In particular, three studies explored the variability of
BACE1 gene expression in AD. In 2019, Wongchitrat
and colleagues measured the rate of BACE1 mRNA ex-
pression in peripheral leukocytes and showed signifi-
cantly higher mRNA levels in ADD patients compared
to HC individuals [44]. In the same year, Vakilian and
colleagues obtained similar results, and in their exten-
sion study, they assessed BACE1 concentration in using
the same blood samples as in the genetic research.
Although they found increased concentrations of BACE1
in ADD patients, they did not observe any correlations
between BACE1 and mRNA expression [45].
A different approach was chosen by Fotuhi and col-
leagues, which evaluated circulating long noncoding
RNA (lncRNA) related to the BACE1 gene (BACE1-AS)
in plasma and plasma-derived exosomes. The lncRNA
BACE1-AS is believed to improve BACE synthesis, via
mRNA stabilization [46].
They did not observe any difference in exosome
lncRNAs; however, they found that lcRNA BACE1-AS
plasmatic concentration was significantly lower in mild
ADD compared to HC individuals, differentiating HC
individuals from mild ADD with good sensitivity and
specificity [46].
Potential explanation of controversial results in
CSF (and blood-based) BACE1 studies
Inconsistent results complicate clinical validation and
qualification of BACE1-related biomarkers and their
potential integration into the evolving AD biomarker
matrix. Existing discrepancies need to be carefully
scrutinized to see whether methodological issues, ra-
ther than biological implications, may determine
differences.
First, as indicated by human neuropathological and ex-
perimental models of aging and AD, BACE1 gene ex-
pression and rates of activity may vary throughout AD
progression. In this context, Rosen and colleagues found
that BACE1 activity was significantly increased in AD
patients with mild dementia compared to patients at
more severe stages [12]. A recent study showed that
BACE1 biomarker candidates are significantly increased
in individuals with MCI, but not with ADD, when com-
pared with the HC group [13]. Therefore, it is likely that
the disease stage of the individual patient may influence
BACE1 concentration and activity, and thus, clinical het-
erogeneity of included individuals may have neutralized
inter-group differences.
Second, since BACE1 had been proposed as a potential
AD-specific biomarker, a considerable part of the re-
ported studies, in particular the older publications, were
performed in clinically, but not biologically, character-
ized study populations. Hence, it is not possible to rule
out that the enrollment of individuals with non-AD
pathophysiology may have biased the data and created
conflicting outcomes.
Most of the recent studies used CSF core biomarkers
of AD, where BACE1 correlated indeed with Aβ and tau
markers. In particular, Mulder and colleagues found that
BACE1 activity was increased in individuals showing
characteristic AD biological features compared to indi-
viduals with negative AD biomarkers [16], while Alexo-
poulos and colleagues showed significantly decreased
CSF BACE1 activity in individuals with MCI without
AD pathophysiology compared to patients with MCI
due to AD [13].
Third, some studies did not report any association be-
tween CSF BACE1 biomarkers and CSF Aβ42 raising
questions about the potential of BACE1 biomarkers in
AD pharmacological trials. However, given the tendency
of Aβ42 monomers of aggregating into oligomers and fi-
brils and preliminary evidence that BACE1 is associated
with Aβ-PET radiotracer uptake, we suggest further
studies using multimodal outcome measures such as
PET tracers and emerging CSF candidates for the assess-
ment of different Aβ species, including Aβ-oligomers
and protofibrils [47–49].
Fourth, conflicting data may be partly explained by
sexual dimorphism in BACE1 biology. Indeed, in a study
conducted in patients suffering from bipolar disorder, a
sex-based dimorphism in BACE1 gene expression levels
was reported, with men displaying upregulation of
BACE1 expression [50].
Furthermore, sexual dimorphism was reported in
males exhibiting higher BACE1 expression compared to
females with schizophrenia and HC individuals [51].
However, female sex-biased dimorphism may exist re-
garding BACE1 concentrations in cognitively healthy in-
dividuals at risk for AD [37]. This finding is in line with
most of the experimental evidence—mouse models of
aging and AD—that indicates that intracellular effects
of estrogens induce upregulation of BACE1 gene ex-
pression levels [32, 52], confirming the widely ac-
cepted notion that women bear higher vulnerability to
AD [53, 54].
Apart from the necessity to elucidate in humans
whether male or female sex may be a determinant of
BACE1 gene expression in AD—where other genetic/
biological factors may synergize with sex hormones or
act independently to upregulate BACE1—evidence of
sexual dimorphism in BACE1 biology may be relevant
for clinical BACE1 inhibitor trial outcomes.
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If a BACE1 sexual dimorphism was corroborated, sex-
related outcome analyses and comparative active treat-
ment dose-finding studies should be taken into account.
Lastly, the abovementioned CSF studies assessed dif-
ferent BACE1 biomarkers and some studies evaluated
BACE1 enzymatic activity [10, 14, 15], while others in-
vestigated either BACE1 protein levels [18] or both
biomarkers.
It should be acknowledged, however, that several
in vitro and animal data point to a non-linear rela-
tionship between the levels of gene expression and
rates of enzyme activity that is highly influenced by
post-translational modifications [55]. Indeed, experi-
mental studies indicate that BACE1 activity signifi-
cantly increases over time while its expression levels
are less likely to be altered during cognitively healthy
aging as well as in the presence of AD-related cogni-
tive decline [3].
Methodological and technological challenges
Inconsistent results in fluid biomarker studies can derive
from methodological differences.
Pre-analytical factors such as the sample collection, pro-
cessing, and storage protocol, as well as analytical factors
including sample handling and immunoassays used, are
likely the most relevant determinants of the inter-study
variability in terms of results (see Tables 1 and 2).
Regarding pre-analytical factors, besides those that
concern AD CSF biomarkers in general, a recent study
conducted in cell lines and iPSC-derived neurons re-
ported that 7 of the 8 BACE1 inhibitors evaluated show
increased BACE1 protein concentrations [66]. A thor-
ough pre-analytical evaluation is required to understand
better the effect of BACE1 inhibitors in BACE1 bio-
marker assays [66].
Regarding the assessment of BACE1 biomarkers,
poor specificity (i.e., other enzymatic activities may
contribute to the signal) of activity-based assays may
represent a plausible explanation for the observed dif-
ferences [39]. In particular, peptide-based activity as-
says show questionable reliability for measuring
BACE1 activity. To our knowledge, one of the most
robust assays used is reported by Sinha and col-
leagues in 1999, utilizing membrane-bound substrates
for measuring BACE1 activity [67]. Specifically, they
purified BACE1 activity to homogeneity from human
brains using a substrate analog inhibitor of the en-
zyme activity [67].
Additionally, antibody-based assays used in the de-
scribed investigations differ in the binding site and epi-
tope recognition. It is plausible to infer that distinct
forms of BACE1 may have been explored in previous
studies.
Moreover, recent research suggests that the exist-
ence of multiple enzyme isoforms could affect the
correct estimation of BACE1 concentration. It is worth
noting that some spliced forms do not have APP-
cleaving activity and that it is not known which (and
whether) specific forms vary in AD [55]. The same
study shows that other enzymes, detectable in CSF,
such as cathepsin B, meprin β, and BACE2, could
exert β-secretase activity.
Some studies employed assays based on polyclonal
antibodies [34, 68], which do not support the reproduci-
bility of the assays on the longer term (cfr. long-term
supply of antibodies with steady characteristics, lot-to-
lot consistency of the assay, etc.). ELISA-based plat-
forms, however, may have non-specificity due to weak
polyclonal antibodies, and this can cause a discrepancy
in data variation between different groups. The stability
of BACE1 protein concentrations measured by sandwich
ELISA shows limited change under standard storage and
freeze/thaw conditions [69].
It will be crucial to develop and standardize the
most appropriate methodologies, to understand the
corresponding readout, and eventually focusing on
CoU qualification to establish the potential role of
BACE1 as an AD biomarker. While the activity-based
measurements encounter low specificity, analyzing
protein concentrations should consider the various
known BACE1 protein isoforms also generated by
post-translational modifications, membrane associ-
ation, and truncated fragments [65]. Indeed, post-
translational modifications influence the rate of
activity of BACE1, thus accounting for a non-linear
association with BACE1 gene expression levels [3].
A relatively easy step forward to increase specificity
and analytical robustness of BACE1 biomarker assess-
ment is to use immunoassays with well-defined anti-
bodies. In this regard, an immunoassay based on two
monoclonal antibodies (mAbs) has been established. It
consists of a clone 10B8 that recognizes BACE1 within
its extracellular, active domain (aa46-240) (aa numbering
of human BACE1) and, as a complementary monoclonal
antibody, clone 5G7, recognizing cleaved, non-
membrane-bound BACE1 via a conformational epi-
tope (aa299-312, a helical region of BACE1, and a
free C-terminal Q386 end). In the first explorative
study with this immunoassay, significant differences
were observed in the CSF from AD patients com-
pared to control individuals [26].
Although still at an initial stage, innovative molecular
imaging for BACE1 assessment is under development. In
line with the high-affinity of BACE1 inhibitors, recent ef-
forts to develop brain-penetrant PET radiotracers, such
as the highly potent selective aminothiazine inhibitor,
PF-06684511 have been made [70].
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Table 1 BACE1 CSF-based biomarkers
BACE1 activity
measured (method)
Antibody Substrate Clinical study Result
Sandwich ELISA Anti-BACE1 Ab SECB1&2 [56, 57]
Anti-BACE1 Ab B280 and anti-




the BACE1 cleavage site
Zhong et al. [59] Significant elevation














Zetterberg et al. [10] Significant differences in
BACE1 activity between
MCI, AD, and HC
Positive correlation
between BACE1 activity,
CSF t-tau, and Aβ40 levels
in the MCI and AD
Sandwich ELISA Anti-BACE1 Ab SECB1&2 [56, 57]
Anti-BACE1 Ab B280 and anti-




the BACE1 cleavage site [59]
Ewers et al. [11] BACE1 activity and protein
levels were significantly
increased in AD compared
to healthy HC
Increase in CSF BACE1 activity
in AD
Increased activity associated
with increased CSF t-tau but










Perneczky et al. [14]
Savage et al. [15]
No significant difference in
BACE1 levels between HC,
MCI, and AD
ELISA mAbs ADx401 (clone 5G7)
and 10B8 and mAb ADx402
(clone 10B8F1) biotinylated
with peroxidase [26]
De Vos et al. [18] Significant correlation of
ratio of CSF neurogranin
trunc P75/BACE1 between
HC, MCI, and AD




Mulder et al. [16] No significant differences
in BACE1 levels between
MCI, AD, and HC




Tsolakidou et al. [62] Positive correlation between
BACE1 activity and SORL1
in CSF t-tau and sAPPβ levels
in AD
Sandwich ELISA Anti-BACE1 monoclonalAbs
(mAbs) 5G7 and 10B8 [26]
Timmers et al. [19] CSF BACE1 correlated
positively with age (weak)






Schaeverbeke et al. [20] Correlation of BACE1 activity
with brain volumes and Aβ
load in regions typically





Grimmer et al. [21] Strong association between
BACE1 activity and in vivo
Aβ pathology in brain regions








Rosén et al. [12] BACE1 correlated slightly
with sAPPα, sAPPβ, and Aβ40




Alexopoulos et al. [63] No significant difference in
BACE1 activity between AD
and HC or MCI while BACE1
activity was significantly
higher in MCI-AD compared
to both HC
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Table 1 BACE1 CSF-based biomarkers (Continued)
BACE1 activity
measured (method)










BACE 1 cleavage site
Ewers et al. [31] CSF BACE1 activity significantly
increased in MCI compared to
AD. No significant difference






Hou et al. [32] BACE1 activity significantly
increased in the hippocampus
of ApoE4/3xTg mice especially
in females
Sandwich ELISA Used anti-BACE1 ectodomain
MAB9311 (R&D Systems) and
detection with rabbit anti-
BACE1 N-terminus B0681
(Sigma–Aldrich) Abs [64]
Decourt et al. [42] BACE1 levels 12% lower
in the AD frontal cortex
compared to HC
6.5% decrease in the
temporal cortex
Solution-based assay Used modified procaspase-




Verheijen et al. [65] Assay detects BACE1 activity
in extracts of human brain tissue
and CSF
Abbreviations: CSF cerebral spinal fluid, MCI individuals with mild cognitive impairment, AD patients with Alzheimer’s disease dementia, HC cognitively healthy
individuals, ELISA enzyme-linked immunosorbent assay, Ab antibody, t-tau total peptide tau protein, Aβ amyloid beta, BACE1 beta secretase1
Table 2 BACE1 blood-based biomarkers
BACE1 activity
(method)




containing the β-cleavage site
(Calbiochem, EMD, Gibbstown,
NJ, USA) [59]
Shen et al. [36] Plasma BACE1 activity
significantly increased by
53.2% in MCI and by 68.9%




terminally labeled with the
fluorescent, Luciferase
Yellow, and N-terminally
labeled with the quenching,
Dabsyl
Cervellati et al. [35] Increased BACE1 activity in
serum of AD
ELISA Biotinylated detector mAb,
diluted in a buffer adapted
for the plasma matrix
Kit-based assay EQ 6541–
9601-L; Euroimmun AG,
Lübeck, Germany [18]
Vergallo et al. [37] Plasma BACE1 significantly
higher in women than in
men in cognitively healthy







Johnston et al. [39] 17% increase in platelet
membrane BACE1 activity








No significant difference in





(Sigma A1472 or Bachem
M2465)
Wongchitrat et al. [44] Baseline platelet membrane
BACE1 activity not significantly
different between MCI vs HC
Immunoassay Immunoassay kit
(CUSABIO, USA)
Vakilian et al. [45] Elevated plasma levels of





Ghafouri-Fard et al. [50] BACE1 levels significantly





Nafisi-Far et al. [51] BACE1 levels significantly
high in schizophrenia
Abbreviations: CSF cerebral spinal fluid, MCI individuals with mild cognitive impairment, AD patients with Alzheimer’s disease dementia, HC cognitively healthy
individuals, ELISA enzyme-linked immunosorbent assay, Ab antibody, t-tau total peptide tau protein, Aβ amyloid beta, BACE1 beta secretase1
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As of other AD PET biomarkers, PET BACE1 ligands
can investigate regional patterns of BACE1 activity and
monitor BACE1 inhibitor regional brain effects.
In summary, pre-analytical and analytical protocols for
BACE1, as well as other biomarkers for AD, should be har-
monized and then standardized at a global scale to drastic-
ally reduce inter-study and longitudinal variability and
eventually speed up the validation and qualification process
of BACE1 biomarker candidates. The validation process
will be facilitated not only by internationally accepted gen-
eral requirements for the competence of testing and cali-
bration laboratories but also by recently proposed standard
operating procedures (SOPs) for Alzheimer’s biomarkers,
including BACE1 (see Table 3 for specific information).
Conclusions: challenges and perspectives
A potential explanation for the observed cognitive wors-
ening in some of the previously reported late-stage
BACE1 inhibitor trials may be related to insufficient
APP substrate specificity. Other physiologically relevant
BACE1 substrates may have been inhibited; some of
these are involved in neuroplasticity, repair, and synaptic
pathways. It may also be possible that BACE1-mediated
APP processing could have been inhibited too strongly
impairing physiological APP turnover or alternative
APP-processing pathways may have been induced. More
extensive research is needed to answer these questions.
Non-clinical, translational studies have shown that
BACE1 activity is a relevant facilitator of axonal
sprouting, dendritic remodeling, and synaptic plasticity,
through both amyloidogenic and non-amyloidogenic
pathways [3, 7]. In this regard, complete suppression of
BACE1 enzymatic activity may substantially impair adult
hippocampal neurogenesis [72, 73], which is a crucial
mechanism for hippocampal synaptic plasticity and es-
sential for memory formation and learning [72, 73].
Experimental studies in adult conditional BACE1
knockout mice indicated that pharmacological BACE1
inhibition might disrupt the organization of axonal path-
ways in the hippocampus [3]. Regarding peripheral tox-
icity, most of the BACE1 inhibitors block the activity of
BACE2 as well, a close homolog of BACE1, which may
cause additional unwanted on-target side effects.
Among several open scientific issues, we highlight the
question of whether the negative correlation between CSF
BACE1 enzymatic activity and degree of hippocampal atro-
phy may be primarily induced by the BACE1 downstream
amyloidogenic effects or on affected synaptic pathways as
well. The interrelation between BACE1 and progressive
neurodegeneration deserves further investigation. Neurode-
generation biomarker panels, including tau and NFL pro-
teins, provide partially differential information of related
pathophysiological processes [74].
There is evidence of a complex interaction between
the amyloidogenic pathway and other pathomechanistic
alterations of AD, including neuroinflammation. TNF re-
ceptor (TNFR1) knockout mice show decreased Aβ pep-
tides and cerebral accumulation of amyloid plaques
Table 3 Proposed stepwise validation path for Alzheimer’s disease biomarkers
Parameter Definition
Robustness The ability of a method to remain unaffected by small variations in method parameters
Precision The closeness of agreement between independent test results obtained under stipulated conditions
Trueness The closeness of agreement between the average value obtained from an extensive series of test results
and an accepted reference value
Uncertainty A parameter associated with the result of a measurement that characterizes the dispersion of the values
could reasonably be attributed to the measurand
Limits of quantification Highest and lowest concentrations of analyte that have been demonstrated to be measurable with
acceptable levels of precision and accuracy
Dilutional linearity Dilutional linearity is performed to demonstrate that a sample with a spiked concentration above the
ULOQ can be diluted to a concentration within the working range and still give a reliable result
Parallelism Relative accuracy from recovery tests on the biological matrix or diluted matrix against the calibrators in
a substitute matrix
Recovery The recovery of an analyte in an assay is the detector response obtained from an amount of the
analyte added to and extracted from the biological matrix, compared to the detector response
obtained for the true concentration of the analyte in the solvent
Selectivity The ability of the bioanalytical method to measure and differentiate the analytes in the presence
of components that may be expected to be present
Sample stability The chemical stability of an analyte in a given matrix under specific conditions for given time intervals
Note: A committee, within the international research framework BIOMARKAPD, recently convened to propose the ten key requirements to fulfill within a step-by-
step validation process. The BIOMARKAPD project aims for the standardization of biomarker measurements for AD and Parkinson’s disease (PD), including pre-
analytical and analytical procedures, assay validation, and development of reference measurement procedures (RMP) and certified reference materials (CRM) for
harmonization of results across assay formats and laboratories. The table captures stepwise standard operating procedures (SOP)
Table adapted from [71]
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through regulation of BACE1 gene expression via the
nuclear factor κB (NF-κB) pathway [75, 76].
Addressing these scientific questions will provide key
pathophysiological insights and facilitate the implemen-
tation of standardized drug-biomarker co-development
programs that are necessary to achieve successful
BACE1 targeting strategies for precision medicine.
BACE1, either in CSF or blood and either activity or
protein concentration, does not show a remarkable per-
formance as a clinical diagnostic or pathognomonic AD
biomarker. However, whether BACE1 biomarkers could
increase diagnostic accuracy if combined with AD core
biomarkers has been poorly investigated. Given the pre-
liminary evidence about the association between BACE1
and Aβ biomarkers as well as neurodegeneration bio-
markers (namely hippocampal volumes and t-tau) and
synaptic biomarkers (neurogranin), we support the in-
vestigation of BACE1 parameters in combination with
the AD core biomarker panel, across different matrixes
such as CFS and blood, to assess diagnostic performance
in the AD continuum (preclinical, prodromal, dementia
stages). Association studies indicate that BACE1 bio-
markers may be useful for COU in a clinical trial setting,
including proof of mechanism, treatment response, and
safety assessment in clinical trials, as well as COU in a
clinical practice setting such as prognostic evaluation in
MCI individuals. From a therapeutic perspective, BACE1
inhibitors dosing could be personalized to engage targets
based on direct concentrations and activity rate mea-
surements from individual bodily fluids [27, 74]. Fur-
thermore, the reduction of cleavage products, such as
sAPPβ, or enriched alternatively processed peptides such
as Aβ5-X, which are correlated to BACE1 inhibition,
could be used to monitor target engagement and
optimize efficacy [15, 77]. Future investigations using
combinatorial strategies and biomarker-guided or per-
sonalized dose selection may allow the application of
lower doses with an optimized specificity for BACE1
over BACE2 [3].
Developing assays for the analysis of Aβ species, includ-
ing bioactive oligomers, provide a more profound under-
standing of human pathophysiology and the relationship
between BACE1 and elements of the downstream amyloid
pathway, from Aβ species supporting synaptic and homeo-
static functions to more bioactive and toxic species [3, 78].
While experimental studies foster knowledge generation
of BACE1’s complex biology, including synaptic homeo-
stasis, BACE1 fluid biomarker development still needs to
transition through the validation and standardization
process with harmonized pre-analytical and analytical
protocols.
From a pharmacological standpoint, BACE1 bio-
markers are expected to be essential components of
drug-biomarker co-development programs supporting
successful outcome generations and lowering drug attri-
tion rates in pipelines targeting BACE1. From a medical
practice standpoint, liquid biopsy with first availability of
CSF followed by maturation of blood-based BACE1 bio-
markers [79] may expand the current descriptive A/T/N
classification system into developing a comprehensive
and integrative biological staging model of AD.
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